Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949104 | 0.93 | CYP1A2 (0.41) | CYP1A2CA1CA2CA4DPP4 | |
| SCHEMBL9949295 | 0.91 | EPHX1 (0.41) | CYP1A2CA1CA2CA4DPP4 | |
| SCHEMBL9950048 | 0.91 | EPHX1 (0.41) | CYP1A2CA1CA2CA4DPP4 | |
| SCHEMBL9949253 | 0.91 | EPHX1 (0.41) | CYP1A2CA1CA2CA4DPP4 | |
| SCHEMBL9949194 | 0.91 | EPHX1 (0.41) | CYP1A2CA1CA2CA4DPP4 | |
| SCHEMBL9949682 | 0.86 | CA1 (0.54) | CYP1A2CA1CA2CA4NOS1 | |
| SCHEMBL1646032 | 0.85 | CYP1A2 (0.35) | CYP1A2DPP4EPHX1 | |
| SCHEMBL28286303 | 0.83 | CYP1A2 (0.59) | CYP1A2CA1CA2CA4DPP4 | |
| SCHEMBL7751399 | 0.81 | EPHX1 (0.36) | CYP1A2CHRNB2CHRNA7CHRNA4EPHX1 | |
| SCHEMBL8855073 | 0.81 | EPHX1 (0.36) | CYP1A2CHRNB2CHRNA7CHRNA4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479159-A1 | PREPARATION METHOD FOR COMPOUND PROVIDED WITH DOUBLE BOND | Sumitomo Chemical Co., Ltd (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120165587-A1 | Method for Producing a Compound with a Double Bond | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165587-A1 | Method for Producing a Compound with a Double Bond | ADH1C, ADH1A, ADH5 | CYP1A2 98/4885CA1 1145/4885CA2 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.